Tyrosine kinase-IN-7

Tyrosine kinase-IN-7 (compound 13h) is an inhibitor of the tyrosine kinase EGFR. The IC50s for inhibiting EGFR (WT) and EGFR (T790M) are 0.630 μM and 0.956 μM respectively. Tyrosine kinase-IN-7 has antitumor activity against four cancer cell lines (HepG2, HCT-116, MCF-7, and A431) with IC50s of 13.02 μM, 10.14 μM, 12.68 μM, and 47.05 μM, respectively[1].

Product Specifications

CAS Number

[345615-74-9]

UNSPSC

12352005

Hazard Statement

H302, H315, H319

Target

EGFR

Type

Reference compound

Related Pathways

JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/tyrosine-kinase-in-7.html

Purity

99.25

Solubility

DMSO : ≥ 100 mg/mL

Smiles

OC1=CC=C(NC2=C3C(CCCC4)=C4SC3=NC=N2)C=C1

Molecular Formula

C16H15N3OS

Molecular Weight

297.37

Precautions

H302, H315, H319

References & Citations

[1]Elmetwally SA, et al. Design, synthesis and anticancer evaluation of thieno[2,3-d]pyrimidine derivatives as dual EGFR/HER2 inhibitors and apoptosis inducers. Bioorg Chem. 2019 Jul;88:102944.